Vertex Pharmaceutic (VRTX)

$457.36 -5.77 (-1.25%)
Market Cap 117.50B
Revenue (ttm) 11.02B
Net Income (ttm) -535.60M
EPS (ttm) N/A
PE Ratio 28.29
Forward PE 27.03
Profit Margin -4.86%
Debt to Equity Ratio 0.00
Volume 1,518,800
Avg Vol 1,473,288
Day's Range N/A - N/A
Shares Out 253.72M
Stochastic %K 85%
Beta 0.32
Analysts Strong Sell
Price Target $489.20

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
Iightning
Iightning Dec. 5 at 1:00 AM
1ightning® Premium Options Alert (Actionable) Ticker: $VRTX Contract: Dec 19 $460C Entry: 7.95 Exit: 11.41 Return: +43.58% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
_GoldenTradingg
_GoldenTradingg Dec. 4 at 11:59 PM
SNSE IS SQUEEZING!!! $KMB $VRTX $DECK $VG $ARES 1
0 · Reply
svertical1
svertical1 Dec. 4 at 11:00 PM
$VRTX $XBI BIOTECH and Vertex should have doubled today! Most important change ever at FDA!
0 · Reply
_GoldenBullys
_GoldenBullys Dec. 4 at 10:18 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $IBKR $VRTX $CAVA $AGX $DEFT %
0 · Reply
svertical1
svertical1 Dec. 4 at 9:35 PM
$VRTX $CRSP $XBI $NTLA If Vertex makes attempt to buy CRSP, they should offer: • $50 per share in cash ($4B) •1 share of Vertex for every 4 shares of CRSP (25M Vertex shares- or $11.5B) Total offer $15B (Cholesterol drug alone eventually pays for this, 100% rev on CASGEVY helps too) Use another $2B for rare disease Fast Track Trials for dozens of genetic diseases. This is where CRSP dropped the ball…Pipeline should be massive!
1 · Reply
svertical1
svertical1 Dec. 4 at 8:01 PM
$VRTX $CRSP $NTLA $EDIT Vertex is clear leader in: CF, SCD, TDT, Pain, Kidney, T1D Imagine then leading genetic engineering after CRSP buy🤞! Use their Billions to begin trials for the Top 100 genetic diseases. Keep 100%!of revenue! All Fast Tracked, with FDA onboard to Insure US Biotech remains preeminent over China and others.
1 · Reply
Iightning
Iightning Dec. 4 at 7:29 PM
1ightning® Premium Options Alert (Actionable) Ticker: $VRTX Contract: Dec 19 $460C Entry: 7.95 Exit: 11.41 Return: +43.58% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 5:32 PM
$VRTX AtomicAlerts® Scalp Alert Direction: SHORT Entry: $458.32 TP1: $457.62 | TP2: $456.92 | TP3: $456.22 Stop Loss: $458.92 EMA9: 458.67 | EMA21: 458.7 RSI14: 50.43 | VWAP: 456.55 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:59 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $457.47 TP1: $458.17 | TP2: $458.87 | TP3: $459.57 Stop Loss: $456.87 EMA9: 457.27 | EMA21: 457.07 RSI14: 54.74 | VWAP: 456.28 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:43 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $457.61 TP1: $458.31 | TP2: $459.01 | TP3: $459.71 Stop Loss: $457.01 EMA9: 457.18 | EMA21: 456.76 RSI14: 58.66 | VWAP: 456.26 Paid Alerts: https://atomicalerts.com
0 · Reply
Latest News on VRTX
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock

Dec 4, 2025, 3:10 PM EST - 8 hours ago

1 Reason I'll Never Sell Vertex Pharmaceuticals Stock

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 11:33 AM EST - 1 day ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Dec 3, 2025, 6:15 AM EST - 1 day ago

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

GOOG GOOGL

3 Top Stocks to Buy in December

Dec 1, 2025, 7:45 PM EST - 3 days ago

3 Top Stocks to Buy in December

MELI TMDX

Where Will Vertex Pharmaceuticals Be in 5 Years

Nov 27, 2025, 6:31 AM EST - 7 days ago

Where Will Vertex Pharmaceuticals Be in 5 Years

2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon

Nov 23, 2025, 10:28 AM EST - 11 days ago

2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon

DXCM

2 Inflation-Proof Growth Stocks That Could Outperform the Market

Nov 20, 2025, 9:53 AM EST - 14 days ago

2 Inflation-Proof Growth Stocks That Could Outperform the Market

MA

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 19, 2025, 4:00 PM EST - 15 days ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Columbia Contrarian Core Fund Q3 2025 Performance Review

Nov 18, 2025, 6:40 AM EST - 16 days ago

Columbia Contrarian Core Fund Q3 2025 Performance Review

EA EBAY ELV INTU TEL

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

Nov 17, 2025, 4:05 PM EST - 17 days ago

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

INCY PFE PPH XBI XLV

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November

Nov 17, 2025, 7:15 AM EST - 17 days ago

1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

Nov 16, 2025, 2:31 PM EST - 18 days ago

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

ARGX ARQT ISRG NVO

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

Nov 12, 2025, 5:09 AM EST - 22 days ago

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

AORT PI PLMR SMTC SPSC

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 2:41 PM EST - 23 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript

Nov 9, 2025, 1:16 AM EST - 25 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 8, 2025, 5:15 PM EST - 26 days ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

Nov 6, 2025, 8:10 AM EST - 4 weeks ago

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

AMZN BSX DKS INSM LHX SPOT TEAM

Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"

Nov 4, 2025, 5:23 PM EST - 4 weeks ago

Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"

Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 4 weeks ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Columbia Balanced Fund Q3 2025 Portfolio Update

Nov 4, 2025, 2:30 AM EST - 4 weeks ago

Columbia Balanced Fund Q3 2025 Portfolio Update

EA EBAY ELV INTU TEL

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 10:06 PM EST - 4 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:20 PM EST - 4 weeks ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 4 weeks ago

Vertex Reports Third Quarter 2025 Financial Results

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Nov 3, 2025, 2:23 PM EST - 4 weeks ago

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

Nov 3, 2025, 7:37 AM EST - 4 weeks ago

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

PFE

Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years?

Nov 3, 2025, 7:00 AM EST - 4 weeks ago

Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years?

NFLX

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Oct 28, 2025, 11:59 AM EDT - 5 weeks ago

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These

Oct 28, 2025, 9:53 AM EDT - 5 weeks ago

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These

NVO

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 27, 2025, 4:00 PM EDT - 5 weeks ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030

Oct 27, 2025, 5:43 AM EDT - 5 weeks ago

Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 23, 2025, 9:00 AM EDT - 6 weeks ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 17, 2025, 9:04 AM EDT - 6 weeks ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

2 Unstoppable Growth Stocks to Buy During a Market Crash

Oct 15, 2025, 4:33 AM EDT - 7 weeks ago

2 Unstoppable Growth Stocks to Buy During a Market Crash

ISRG

4 Healthcare Stocks to Buy Now

Oct 12, 2025, 9:45 AM EDT - 7 weeks ago

4 Healthcare Stocks to Buy Now

CRSP NTLA RXRX

Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500

Oct 7, 2025, 3:15 AM EDT - 2 months ago

Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500

PFE

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 6, 2025, 4:00 PM EDT - 2 months ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

2 Beaten-Down Stocks Primed for a Comeback

Oct 5, 2025, 2:30 PM EDT - 2 months ago

2 Beaten-Down Stocks Primed for a Comeback

NVO

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

Oct 2, 2025, 1:31 PM EDT - 2 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Sep 25, 2025, 1:39 PM EDT - 2 months ago

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 2 months ago

Vertex Announces Key Advancements Across Kidney Portfolio

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Sep 23, 2025, 9:00 AM EDT - 2 months ago

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 7:53 AM EDT - 2 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon

Sep 20, 2025, 9:45 AM EDT - 2 months ago

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon

PFE

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Sep 18, 2025, 8:30 AM EDT - 2 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Why This Biotech Company Could Be a Growth Stock Powerhouse

Sep 17, 2025, 5:10 AM EDT - 2 months ago

Why This Biotech Company Could Be a Growth Stock Powerhouse

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals

Sep 15, 2025, 7:30 AM EDT - 2 months ago

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals

Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality

Sep 13, 2025, 8:19 AM EDT - 2 months ago

Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality

3 Absurdly Cheap Stocks to Buy for the Long Haul

Sep 12, 2025, 7:30 AM EDT - 2 months ago

3 Absurdly Cheap Stocks to Buy for the Long Haul

CMCSA UPS

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Sep 11, 2025, 9:05 AM EDT - 3 months ago

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:01 PM EDT - 3 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Iightning
Iightning Dec. 5 at 1:00 AM
1ightning® Premium Options Alert (Actionable) Ticker: $VRTX Contract: Dec 19 $460C Entry: 7.95 Exit: 11.41 Return: +43.58% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
_GoldenTradingg
_GoldenTradingg Dec. 4 at 11:59 PM
SNSE IS SQUEEZING!!! $KMB $VRTX $DECK $VG $ARES 1
0 · Reply
svertical1
svertical1 Dec. 4 at 11:00 PM
$VRTX $XBI BIOTECH and Vertex should have doubled today! Most important change ever at FDA!
0 · Reply
_GoldenBullys
_GoldenBullys Dec. 4 at 10:18 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $IBKR $VRTX $CAVA $AGX $DEFT %
0 · Reply
svertical1
svertical1 Dec. 4 at 9:35 PM
$VRTX $CRSP $XBI $NTLA If Vertex makes attempt to buy CRSP, they should offer: • $50 per share in cash ($4B) •1 share of Vertex for every 4 shares of CRSP (25M Vertex shares- or $11.5B) Total offer $15B (Cholesterol drug alone eventually pays for this, 100% rev on CASGEVY helps too) Use another $2B for rare disease Fast Track Trials for dozens of genetic diseases. This is where CRSP dropped the ball…Pipeline should be massive!
1 · Reply
svertical1
svertical1 Dec. 4 at 8:01 PM
$VRTX $CRSP $NTLA $EDIT Vertex is clear leader in: CF, SCD, TDT, Pain, Kidney, T1D Imagine then leading genetic engineering after CRSP buy🤞! Use their Billions to begin trials for the Top 100 genetic diseases. Keep 100%!of revenue! All Fast Tracked, with FDA onboard to Insure US Biotech remains preeminent over China and others.
1 · Reply
Iightning
Iightning Dec. 4 at 7:29 PM
1ightning® Premium Options Alert (Actionable) Ticker: $VRTX Contract: Dec 19 $460C Entry: 7.95 Exit: 11.41 Return: +43.58% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 5:32 PM
$VRTX AtomicAlerts® Scalp Alert Direction: SHORT Entry: $458.32 TP1: $457.62 | TP2: $456.92 | TP3: $456.22 Stop Loss: $458.92 EMA9: 458.67 | EMA21: 458.7 RSI14: 50.43 | VWAP: 456.55 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:59 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $457.47 TP1: $458.17 | TP2: $458.87 | TP3: $459.57 Stop Loss: $456.87 EMA9: 457.27 | EMA21: 457.07 RSI14: 54.74 | VWAP: 456.28 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 3:43 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $457.61 TP1: $458.31 | TP2: $459.01 | TP3: $459.71 Stop Loss: $457.01 EMA9: 457.18 | EMA21: 456.76 RSI14: 58.66 | VWAP: 456.26 Paid Alerts: https://atomicalerts.com
0 · Reply
QuietTrader
QuietTrader Dec. 4 at 2:38 PM
$CRSP There have been rumors swirling for the past few months. What I'm hearing is that there may be multiple parties involved, including the rumored $VRTX and $AMGN. I wouldn't be surprised if $LLY throws her hat in the mix, as Eli Lilly is aggressively expanding into gene‑editing and biotech via acquisitions and collaborations. In 2025 alone, Lilly bought a gene‑editing firm (showing its willingness to invest in this space). I only hope they don't rush into decisions, because this company has the ingredients to succeed and do very well for its investors on its own.
1 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 2:23 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $463.22 TP1: $463.92 | TP2: $464.62 | TP3: $465.32 Stop Loss: $462.62 EMA9: 463.13 | EMA21: 462.92 RSI14: 53.07 | VWAP: 447.99 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 2:06 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $463.22 TP1: $463.92 | TP2: $464.62 | TP3: $465.32 Stop Loss: $462.62 EMA9: 463.13 | EMA21: 462.92 RSI14: 53.07 | VWAP: 447.99 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:48 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $463.22 TP1: $463.92 | TP2: $464.62 | TP3: $465.32 Stop Loss: $462.62 EMA9: 463.13 | EMA21: 462.92 RSI14: 53.07 | VWAP: 447.99 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 12:32 PM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $463.22 TP1: $463.92 | TP2: $464.62 | TP3: $465.32 Stop Loss: $462.62 EMA9: 463.13 | EMA21: 462.92 RSI14: 53.07 | VWAP: 447.99 Paid Alerts: https://atomicalerts.com
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 4 at 11:15 AM
$VRTX AtomicAlerts® Scalp Alert Direction: LONG Entry: $463.22 TP1: $463.92 | TP2: $464.62 | TP3: $465.32 Stop Loss: $462.62 EMA9: 463.13 | EMA21: 462.92 RSI14: 53.07 | VWAP: 447.99 Paid Alerts: https://atomicalerts.com
0 · Reply
victorgn
victorgn Dec. 4 at 9:19 AM
Morgan Stanley knows best $VRTX Morgan Stanley upgraded Vertex Pharmaceuticals (VRTX) to Overweight from Equal Weight with a price target of $516, up from $438. The firm is taking a more positive stance on the company's kidney franchise pipeline, including Pove and Inaxaplin.
0 · Reply
RunnerSignals
RunnerSignals Dec. 4 at 4:27 AM
$AMD $MCHP $META $RIVN $VRTX Options Trading Signals Where Big-Money Moves https://stocksrunner.com/news/2025-12-03-options-trading-signals-where-big-money-moves
0 · Reply
Iightning
Iightning Dec. 4 at 3:13 AM
1ightning® Premium Options Alert (Actionable) Ticker: $VRTX Contract: Dec 19 $470C Entry: 7.00 Exit: 9.63 Return: +37.57% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
JInvestTrade
JInvestTrade Dec. 4 at 12:32 AM
$VRTX https://www.linkedin.com/posts/ashima-m-868a2011b_medicalbreakthrough-diabetescure-futuremedicine-activity-7401683284486995971-sab3?utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
RunnerSignals
RunnerSignals Dec. 3 at 10:09 PM
$MCHP $GENI $VRTX all crushing their 200-day MA! volume exploding across the board https://stocksrunner.com/news/2025-12-03-daily-market-pulse-and-advanced-technical-analysis
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 3 at 9:28 PM
$VRTX what a monster day- I'm so glad I picked up the dip at $385
0 · Reply